A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GLPG3667 in Adult Subjects With Active Systemic Lupus Erythematosus
Latest Information Update: 20 Mar 2025
At a glance
- Drugs GLPG 3667 (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms GALACELA
- Sponsors Galapagos NV
Most Recent Events
- 14 Mar 2025 Planned End Date changed from 1 Apr 2026 to 1 Mar 2026.
- 14 Mar 2025 Planned primary completion date changed from 1 Dec 2025 to 1 Oct 2025.
- 14 Mar 2025 Status changed from recruiting to active, no longer recruiting.